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ABSTRACT
Due to superior survival in the short to medium term, the first-generation ABL kinase inhibitor imatinib
mesylate has generally supplanted all other therapies as the initial treatment of choice in chronic phase chronic
myeloid leukemia. The role of allogeneic stem cell transplantation (alloSCT) has shifted from a preferred
first-line therapy to a possible second- or third-line therapy. However, despite generally excellent responses to
imatinib, some patients respond poorly or lose response, and the risk-benefit equation in these cases may
rapidly shift in favor of the alloSCT option. These patients need to be identified as soon as possible so that the
alloSCT option can be applied while they are still in controlled chronic phase. Monitoring of imatinib response
in patients who have suitable donors and are potentially eligible for alloSCT needs to be frequent, sensitive,
and accurate. Clear criteria for switching from imatinib therapy to the alloSCT option should be established
for each patient according to the specific risk profile of the transplant. The potential efficacy and safety of
clinical trials combining reduced intensity alloSCT with ABL kinase inhibitor therapy warrants further
consideration.
© 2006 American Society for Blood and Marrow Transplantation
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The ABL tyrosine kinase inhibitor imatinib has
ecome the standard ﬁrst-line therapy for nearly all
atients with newly diagnosed chronic phase chronic
yeloid leukemia (CML), even though allogeneic
tem cell transplantation (alloSCT) remains the only
roven curative therapy. Although imatinib dramati-
ally decreases the risk of disease progression in CML,
t rarely, if ever, eradicates the leukemic clone and
merging resistance is an ongoing concern. As a con-
equence, patients and clinicians need to regularly
eview the response to imatinib and be prepared to
witch therapeutic strategies if a good molecular re-
ponse to imatinib is not achieved or not maintained.
ased on the most recent data on the safety and
fﬁcacy of these 2 approaches, it is timely to address 2
uestions: (1) Is imatinib always the best ﬁrst-line
ption? (2) If alloSCT is reserved for second-line
herapy, when should it be applied? This review dis-
usses the current safety and efﬁcacy of both ap- lroaches and makes some recommendations based on
he evidence available, which we recognize are open to
hallenge and are likely to change as new evidence
ecomes available.
AFETY AND EFFICACY OF ALLOSCT IN 2005
yeloablative Allografts with Sibling Donors
The most recent large series is from the Seattle
roup in 2003 [1]. Between 1995 and 2000, 131 con-
ecutive patients with CML in ﬁrst chronic phase
CP1) received conditioning with targeted busulphan
oses and cyclophosphamide followed by infusion of
tem cells, most of which were collected from marrow
n 100) rather than peripheral blood (n 31). Most
atients (n  114) underwent transplantation within a
ear of diagnosis. The estimated probabilities at 1 year
nd 3 years, respectively, of nonrelapse transplant-
elated mortality (TRM) were 10% and 14%, of re-
apse 3% and 8%, and of survival 91% and 86%.
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A. Grigg and T. Hughes796Although less relevant for early TRM than recent
eries, registry studies provide relevant data on long-
erm complications, including late relapse. An Inter-
ational Bone Marrow Transplant Registry (IBMTR)
eview documented a cytogenetic and/or hematologic
elapse rate of 17% between 5 and 15 years after
ibling allografting for CML-CP1 and a 5% to 7%
umulative incidence of TRM over this period [2].
elapses may not affect substantially survival; how-
ver, because reversion to a durable second remission
n most late relapses can be achieved by 1 of, or a
ombination of, imatinib, donor leucocyte infusion, or
nterferon [3-7].
Recent advances in molecular monitoring have
llowed early detection of relapse after transplanta-
ion, often before cytogenetic or overt hematologic
elapse [8]. Imatinib is particularly effective in induc-
ng cytogenetic and molecular remission in this con-
ext and may be preferable to donor leukocyte infu-
ions, which have a higher risk of graft-versus-host
isease (GVHD) [4]. However, the durability of ima-
inib-induced remissions, the effectiveness in patients
n whom imatinib before transplantation fails, and the
equirement for long-term imatinib therapy in this
ontext are issues that are not yet resolved [7].
yeloablative Transplants with Unrelated Donors
An analysis by the National Marrow Donor Pro-
ram of transplantations between 1988 and 1999 for
ML-CP1 within a year of diagnosis found that
-year disease-free survivals of matched unrelated re-
ipients 30 and 30-40 years old were 61% and 57%,
espectively [9]. Outcome was only signiﬁcantly worse
han sibling allografts if the transplantation was per-
ormed 1 year after diagnosis and/or the recipient
as 30 years old.
The current situation may be a little different.
ecent improvements in molecular matching of unre-
ated donors have led to lower TRM [10]. In a report
rom the Seattle group, patients 50 years old who
nderwent transplantation within a year of diagnosis
rom an HLA-A, -B, and -DRB1-matched donor and
able 1. PBSC Versus BM-Related Donor Allografts for CML-CP1* ,†
Design† Patients, n TRM
ingle-institution retrospective
review [15]
71 NA
ulticenter randomized [16] 62 No difference
eta-analysis [17] 423 No difference
BM indicates bone marrow; NA, not available.
All HLA-matched sibling donors apart from a small number of m
Cytogenetic or hematologic, not molecular.eceiving modern antimicrobial prophylaxis had an
stimated 3-year overall survival of 87% (95% conﬁ-
ence interval, 74-99) [11]. This suggests that an un-
elated donor allograft may be a reasonable consider-
tion in some younger patients without a sibling
onor who have a suboptimal response or lose re-
ponse to imatinib.
retransplantation Factors Influencing Outcome
The European Group for Blood and Marrow
ransplantation (EBMT) registry, using transplant
ata from 1989 to 1996, found that favorable factors
ere donor source (HLA-identical sibling vs unre-
ated), disease stage (CP1 vs later phase), recipient age
20, 20-40, 40 years), sex combination (other vs
ale recipient/female donor), and time from diagnosis
o transplantation (12 vs 12 months) [12]. A prog-
ostic EBMT scoring system derived from these fac-
ors was recently validated by a separate IBMTR study
13]. In contrast, the recent single institution Seattle
tudy, which enrolled patients between 1995 and
000, did not demonstrate a trend to any effect of age
40, 40-50, 50 years) or patient/donor gender
ombinations (P .55 and .42, respectively), but there
as a trend for increased mortality with a longer time
rom diagnosis to transplantation (P  .10) [1].
ptimal Myeloablative Conditioning Regimen
Cyclophosphamide plus total body irradiation has
een compared with busulphan plus cyclophospha-
ide in CP1, with no conclusive evidence that either
egimen is superior with respect to overall survival and
elapse or nonrelapse mortality [14].
tem Cell Source
Published reports from single institutions, pro-
pective randomized studies, and a recent meta-anal-
sis have evaluated the outcome of peripheral blood
tem cells (PBSCs) versus marrow sibling allografts
or CML-CP1 (Table 1) [15-17] (Schmitz N, personal
ommunication). The results suggest that PBSCs pro-
Relapse‡
Extensive Chronic
GVHD Survival
r 4 y cytogenetic
pse with BM
< .006)
NA No difference
to higher with BM
 .10)
Trend (P  .11) to
higher with PBSC
No difference
r with BM (P  .0023) Higher (P < .00001)
with PBSC
No difference
hed related donors (17 of 556).Highe
rela
(P
Trend
(P
Highe
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Allografting for CML in the Imatinib Era 797uce a lower cytogenetic and hematologic relapse rate
nd a higher incidence of extensive chronic GVHD,
ith no effect on TRM or survival, with the latter
resumably due to effective salvage. Although there
re insufﬁcient data from these papers to evaluate the
ffect of chronic GVHD on quality of life (QOL),
ther reports have demonstrated poorer QOL with
xtensive chronic GVHD [18]. In the Seattle series of
redominantly marrow allografts, only 10% of survi-
ors had a Karnofsky score 80% [1].
ffect of GVHD on Outcome
A retrospective EBMT analysis of 4000 allo-
rafts for CML-CP1 found that survival was best in
atients with limited chronic GVHD because the risk
f relapse was (1) equivalent to that of extensive
hronic GVHD with lower TRM or (2) lower than
hat of no chronic GVHD with equivalent TRM [19].
Overall, these studies suggest that given (1) the
ncreased risk of extensive chronic GVHD with
BSCs and its adverse effect on QOL and (2) the
bsence of a survival advantage with PBSCs, marrow is
he preferred source of stem cells for sibling allografts
n CML-CP1, at least in patients without prior expo-
ure to imatinib. However, it is conceivable that prior
matinib resistance increases the risk of relapse after
llografting, in which case PBSCs may be preferable
ue to the lower risk of relapse. There are insufﬁcient
ata to recommend a preferred stem cell source for
nrelated donor allografts.
educed Intensity Conditioning
Reduced intensity conditioning regimens such as
udarabine (ﬂu)-busulphan have been associated in a
mall series of patients with CML and relatively short
ollow-up with a low risk of TRM and relapse [20].
evertheless, a concern is that the incidence and se-
erity of chronic GVHD may not be substantially
ifferent after reduced intensity compared with my-
loablative PBSC allografts [21]. There are conﬂicting
ata as to whether the graft-versus-CML effect obvi-
tes aggressive conditioning and allows very low dose
egimens such as ﬂu/low-dose total body irradiation
22] or ﬂu-cyclophosphamide [23] to be effective. A
etrospective EBMT analysis suggested a lower risk of
elapse with ﬂu-busulphan compared with ﬂu-cyclo-
hosphamide or low-dose total body irradiation, but
he numbers of patients in CP1 included in this study
ere too small to draw deﬁnitive conclusions [24]. A
romising experimental approach that warrants fur-
her assessment is initial disease reduction with ima-
inib followed by a reduced intensity allograft (see
uture Prospects section). outografts
In the pre-imatinib era there was considerable
nterest in autografting for CML in patients without
n allograft option by using unpurged Philadelphia
hromosome-positive (Ph) stem cells collected at di-
gnosis or in vivo purged predominantly Philadelphia
hromosome-negative (Ph) stem cells collected after
nterferon or chemotherapy [25,26]. Current recom-
endations in Australasian Leukemia Group studies
ave included the collection of granulocyte colony-
timulating factor mobilized PBSCs in imatinib-
reated patients who achieve a complete cytogenetic
esponse (CCR) [27]. The rationale is to consider a
ater autograft by using these cells if there is subse-
uent progression. In practice there is little current
xperience with this approach because the vast major-
ty of patients have maintained their response to ima-
inib in the short to medium term.
AFETY AND EFFICACY OF IMATINIB IN 2005
The pivotal International Randomized Study of
nterferon Versus STI571 (IRIS) study in newly diag-
osed CML compared imatinib 400 mg daily with
nterferon- and cytosine arabinoside. After an aver-
ge of 38 months of follow-up, 96% of patients re-
eiving imatinib achieved a complete hematologic re-
ponse (CHR), 88% a major cytogenetic response
MCR; Ph 65%), and 81% a CCR [28] The esti-
ated progression-free survival at 42 months was
4%; progression in this context was deﬁned as the
evelopment of accelerated phase (AP) or blast crisis
BC), loss of CHR or MCR, or death from any cause.
he incidence of AP or BC was approximately 2% per
ear for the ﬁrst 3 years of follow-up, with a lower
ncidence (.9%) in the fourth year. Most responding
atients had progressive improvement in their molec-
lar response, as deﬁned by quantiﬁcation of BCR-
BL, even in the third or fourth year of therapy [29].
onger follow-up is clearly required, however, be-
ause, even in responding patients, there are concerns
bout the long-term risk of resistance. The ongoing
isk of mutations in a study of mainly late chronic
hase patients was approximately 5% in each of the
rst 2 years after achieving CCR [30].
Early results from nonrandomized dose escalation
tudies have demonstrated a higher rate of MCR and
CR and superior molecular responses by 12 months
ompared with historical controls receiving 400 mg
31,32]. Whether this superior early response ulti-
ately translates into lower rates of progression and
mproved long-term survival is unknown. These issues
ill be addressed by the recently activated randomized
tudies, which compare daily doses of 400 with 800 mg
f imatinib as initial therapy.
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A. Grigg and T. Hughes798OMPARISONS BETWEEN IMATINIB AND
LLOGENEIC TRANSPLANTATION
urvival
Figure 1 compares the short-term survival curves
f patients with CML-CP1 and treated with imatinib
ith those undergoing HLA-identical sibling al-
ografting as reported by the Center for International
lood and Marrow Transplant Research (CIBMTR).
lthough these groups may not be equivalent with
espect to age and underlying prognostic factors (me-
ian age, 50 years; 62% male in IRIS study; median
ge, 37 years; 58% male in CIBMTR cohort), it is
lear that early survival is higher in the imatinib
roup. It is not known when or if these survival curves
ill cross with longer follow-up. If the survival curve
or imatinib recipients eventually falls below that of
llograft recipients, it seems likely, based on current
rends, that the crossover point will be well beyond 10
ears.
Using the cytogenetic response data from the
RIS study and long-term survival data according to
ytogenetic response from a prior study with inter-
eron and low-dose cytosine arabinoside, the esti-
ated life expectancy after treatment with imatinib
lone was 15.3 years [33]. This estimate does not
ake into account strategies to improve the cytoge-
etic response such as higher initial doses of ima-
inib, dose escalation in suboptimal responders,
ewer more potent tyrosine kinase inhibitors, or the
ffect of an allograft in patients who do not respond
o imatinib or respond but whose disease subse-
igure 1. Survival after HLA-identical sibling myeloablative transpla
ollow-up of 18 months (range,1-70). These data are preliminary a
ranted by Mary Horowitz, MD). These are compared with surv
000-2001, with data analyzed in July 2004, a median follow-up of 4
4  2%, and 73  2%, respectively, after transplantation. Probab
%, and 91%, respectively. BMT indicates bone marrow transplanuently progresses. Aolecular Remission
A German group recently compared the durability
f molecular remissions in imatinib versus allograft
ecipients [34]. The projected risk of molecular re-
apse at 12 months after the ﬁrst negative molecular
est was 83% versus 20%, respectively, suggesting that
he “quality” of molecular remission was superior in
he allograft group. This may reﬂect a more gradual
ecrease in the rate of leukemia on imatinib therapy.
or this reason, imatinib recipients tend to ﬂuctuate
etween polymerase chain reaction positive and neg-
tive for a longer period before becoming consistently
olymerase chain reaction negative. However, 20%
f patients treated with imatinib for 3 to 4 years have
CR-ABL transcript levels consistently below the
evel of detection [29], in contrast to most allograft
urvivors.
Complete eradication of CML is unlikely with
matinib alone because primitive, quiescent Ph
tem cells are insensitive to imatinib in vitro and
cr-abl–positive CD34 progenitors may persist in
ong-term recipients of imatinib [35,36]. Although
he “emergence” of abnormal clones in Ph cells
as been reported, its long-term signiﬁcance is un-
lear because cytogenetic abnormalities are often
ransient, seen in only a few metaphases and not
enerally associated with morphologic evidence of
yelodysplasia [37,38]. Advanced myelodysplasia or
cute myeloid leukemia was observed in only 2 of
186 patients with CML (.1%), both with mono-
omy 7, who were treated with imatinib at MD
s (n 1373) for CML-CP1 between 2000 and 2005, with a median
e obtained from the Statistical Center of the CIBMTR (permission
ing imatinib from the IRIS trial; 553 patients were recruited in
ths [28]. Probabilities of survival at 1, 3, and 5 years were 81  1%,
f survival at 1.5, 2, and 3.5 years after imatinib were 97.2%, 96 ntation
nd wer
ival us
2 mon
ilities onderson [39].
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Allografting for CML in the Imatinib Era 799uality of Life
The QOL of 5l long-term survivors after al-
ografting (mainly marrow) for CML was recently
eported [40]. Compared with an age-adjusted refer-
nce population, transplantation survivors had im-
aired role function and cognition and sexual func-
ioning, but relatively normal scores for physical
unction. The published QOL data for imatinib is not
irectly comparable, but generally the drug does not
igniﬁcantly adversely affect physical function and
ell-being [41]. Serious side effects of imatinib in-
lude pneumonitis [42], severe skin reaction [43], re-
al failure [44], hepatic necrosis [45], and various ﬂuid
etention syndromes such as pleuropericardial effu-
ions [46], cardiac tamponade [47], cerebral edema
48], and severe periorbital edema that causes visual
bstruction [49]. However, these are uncommon and,
nlike severe GVHD, usually rapidly reversible with
essation of therapy without long-term sequelae.
Myeloablative allografts cause infertility in most
atients, although spermatogenesis may recur in some
en [50]. The effect of imatinib on male and female
ertility is largely unknown. Azoospermia has been
eported in a single case [51], but the frequency, se-
erity, and reversibility of sperm count reduction has
ot been characterized in an interpretable cohort of
atients. When relevant, sperm cryopreservation be-
ore commencing imatinib should be discussed. Al-
hough pregnancies in partners of male patients have
sually resulted in the birth of health infants [52], data
re limited and sexually active males should be advised
o use contraception. Similarly, the effect of imatinib
n fertility and pregnancy outcome in women has not
een comprehensively studied. Although a recent se-
ies suggested there was no evidence that brief expo-
ure to imatinib during conception and pregnancy
dversely affected development [53], fatal and severe
onfatal congenital abnormalities have been reported
54]. These observations, together with teratogenicity
n rats, means that administration of imatinib to preg-
ant women currently poses an unacceptable risk and
ffective contraception should be used during therapy
o prevent pregnancy.
onor Searches for Patients on Imatinib
For younger patients who are potential candidates
or an allograft if their response to imatinib is subop-
imal or they develop resistance, is it necessary to
roceed with a donor search immediately after diag-
osis? Because 80% of patients will not have an
ndication for allografting in the ﬁrst 5 years, the cost
ffectiveness of this approach needs to be considered.
owever, based on the IRIS study, 3% to 5% of de
ovo patients will develop resistance in the ﬁrst year,
% to 10% will have a suboptimal response, and the
ccasional patient may suddenly develop rapidly pro- Fressive disease [55]. Because a search for an unrelated
onor can often take many months, donor searches
mmediately after diagnosis are probably justiﬁed for
atients who would be considered potential allo-
raft candidates if they develop resistance to medi-
al therapy.
S IMATINIB THE BEST FIRST-LINE OPTION FOR ALL
E NOVO CHRONIC PHASE CML PATIENTS?
Although it is generally accepted that most pa-
ients with de novo CML should receive imatinib as
rst-line therapy, it is possible that a subset of patients
ould be identiﬁed who would be expected to respond
oorly to imatinib and might be appropriate candi-
ates for a ﬁrst-line allograft. With currently available
rognostic indicators, can such a group be identiﬁed?
actors Predictive of a Suboptimal Response
o Imatinib
There are a number of in vitro and clinical fea-
ures that may be useful in identifying patients with
poor or suboptimal response to imatinib who may
eneﬁt from an allograft.
The Sokal and Hasford prognostic scores are
omewhat discriminatory. The rates of CCR by 12
onths in Sokal high, intermediate, and low groups
re 49%, 67%, and 76%; the respective rates of major
olecular response (MMR;3 log reduction in BCR-
BL) are 18%, 30%, and 50% [56]; and those of
stimated survival at 42 months are 84%, 91%, and
4% [28]. Of note, Sokal risk group is not discrimi-
atory for survival in patients achieving a CCR [28].
nvestigators have demonstrated that in vitro sensitiv-
ty to imatinib-induced inhibition of ABL kinase ac-
ivity is predictive of molecular response in de novo
ML, particularly in patients with a low Sokal score
57]. There is somewhat conﬂicting literature on
hether imatinib overcomes the adverse prognostic
igniﬁcance of deletions of the derivative chromosome
[58,59]. Of note, allografting reverses the poor prog-
osis of this abnormality [60].
Overall, however, none of these variables is sufﬁ-
iently predictive in their current form to argue
gainst a trial of imatinib in a speciﬁc patient subset.
n current practice it is the early response to imatinib
hat is more clinically relevant.
linically Relevant Definition of Suboptimal
esponse to 400 mg/d
Hematologic. To our knowledge, there are no pub-
ished data on the outcome in the small percentage of
atients, in the order of 6% to 7%, who do not achieve
CHR within the ﬁrst 6 months. However, it is likely
hat the outcome of these patients is not favorable.
ailure to achieve a CHR should be conﬁrmed with
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A. Grigg and T. Hughes800ytogenetic and molecular analyses because persistent
eucocytosis or thrombocytosis may be due to causes
ther than resistant disease.
Cytogenetics. Analysis of the IRIS study showed
hat most patients (55% to 68%) who achieved no,
inimal (60% to 95% Ph), or minor (36% to 65%
h) at 3 months achieved a CCR at 32 months [61].
t 6 months, the response was more discriminatory:
lthough approximately 50% of patients with a mini-
al or minor response still achieved a CCR at 42
onths, this occurred in only 25% of those with no
esponse. This has led to the proposal that achieving
t least a minimal cytogenetic response at 6 months is
n important parameter for continuing imatinib [61].
Practically, however, the most relevant clinical
ndpoints are rates of progression and survival. IRIS
ata demonstrate that for patients who achieved MCR
ithin 6 months, the estimated transformation-free
urvival (transformation deﬁned as accelerated or blas-
ic phase) at 30 months is 97% versus 89% for those
ho did not (P  .001). The estimated survival at 30
onths for the same patients was 97% versus 92%,
espectively (P  .02). Achievement or not of a MCR
t 12 months appears to be even more discriminatory,
ith the rate without progression to AP/BC at 42
onths being 97% and 73% (P  .001) and estimated
urvival at this time being 95% and 83% (P  .001),
espectively [28]. Failure to achieve CCR (equivalent
o a 2 log reduction in BCR-ABL) at 12 months
esulted in an approximate 19% risk of progression
ver the next 2 years [62].
How best to use these data in making therapeutic
ecisions is difﬁcult. A key issue is whether interven-
ion (see next section) is warranted in patients with a
suboptimal” early response who are still likely statis-
ically to ultimately respond and have a favorable out-
ome. Ideally, the effect of any therapeutic interven-
ion should be assessed prospectively in a clinical trial.
n the absence of this, we argue for an aggressive
pproach on the basis that higher initial doses and
arly dose intensity have been associated with higher
olecular and cytogenetic responses [31,32]. Accord-
ngly, we contend that early dose escalation is a rea-
onable consideration in patients who do not achieve
CR by 6 months or CCR by 12 months, based on
he signiﬁcantly higher risk of transformation and
eath. Mutation analysis, as will be discussed, may be
ery useful in this context by allowing therapy tailored
o drug sensitivity of the predominant leukemic clone.
Molecular. Failure to achieve a MMR by 12 months
s associated with a signiﬁcantly lower probability of
rogression-free survival over the next 3 years (93% vs
00%) [62]. However, the Australian substudy showed
hat a signiﬁcant number of IRIS patients who had not
chieved MMR at 12 months went on to achieve it by
8 months [28], but very few not in MMR at 18
onths achieved MMRwith longer follow-up. There- tore, failure to achieve MMR should be regarded as a
uboptimal response only if not achieved by 18
onths.
PTIONS IF SUBOPTIMAL RESPONSE
R RESISTANCE TO IMATINIB
ose Escalation
There have been no systematic studies to deter-
ine under what circumstances an increase in ima-
inib dose is likely to lead to an improved cytogenetic
nd/or molecular response. Early experience suggests
hat dose escalation in suboptimal responders can be
ssociated with substantial improvements in response,
articularly in those with cytogenetic rather than he-
atologic resistance [63]. Subsequent investigators re-
orted that dose escalation led to durable response in
nly 25% of patients who did not achieve a CCR on
00 mg [64,65]. Responses were limited essentially to
atients with some degree of initial Ph negativity; only
of 18 patients with 100% Ph had sustained cyto-
enetic improvement [64].
For patients with a suboptimal response (as de-
ned earlier) to imatinib 400 to 600 mg/d, it is rea-
onable to increase the dose to 800 mg/d (or maximal
olerated dose if this is800 mg/d). After another 3 to
months on the higher dose, if there has been no
mprovement in cytogenetic response, a change of
herapy should be considered.
Mutation analysis may be very useful in determin-
ng the appropriateness of dose escalation. Patients
ho respond suboptimally and those with a persistent
2-fold increase in BCR-ABL transcript levels should
deally have analysis performed [66]. With ABL kinase
utations, there is usually a steady increase in the
evel of BCR-ABL transcripts, thus supporting the
otion that the mutant leukemic clone is able to ex-
and because of the relatively low level of imatinib-
nduced kinase inhibition in the mutant clone. Over-
ll, the effect of dose escalation in patients with
utations is likely to be modest, with cytogenetic or
olecular improvement in only 2 of 42 such cases
eported recently by a German group [67]. Neverthe-
ess, others have demonstrated that higher doses of
matinib can lead to a decrease in BCR-ABL transcript
evels and cytogenetic improvement in selected cases
n which mutation-related resistance is minor or mod-
rate. Therefore, in the absence of alternative thera-
ies, it seems reasonable to increase the dose of ima-
inib to 800 mg/d when low-level resistant mutations
ave emerged at lower doses. The mutant T315I, is
ompletely resistant to imatinib in vitro and in vivo
68,69] and other mutations, particularly in the P
oop, are also unlikely to respond to dose increases but
his is not certain [70-72].
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Allografting for CML in the Imatinib Era 801ew Tyrosine Kinase Inhibitors
Dasatinib (BMS-354825, Bristol-Myer Squibb,
allingford, CT) is a dual SRC/ABL kinase inhibitor
ith 300-fold greater potency in vitro than imatinib
nd preclinical activity against most imatinib-resistant
CR-ABLmutants [73]. Preliminary results of a phase
dose escalation study have demonstrated promising
ctivity of this agent in patients with imatinib intoler-
nce or resistance [74]. In 40 patients in CP, the rates
f CHR, MCR, and CCR were 88%, 40%, and 33%,
espectively, with responses maintained at a median
ollow-up of 13 months. MMR occurred in 4 of 19
valuated patients [75]. Of concern is the emergence
f the resistant T3151 mutation in 6 of 33 patients
ho received BMS-354825 for CP or AP/BC, which
as associated in each case with signiﬁcant increases in
CR-ABL transcript levels [75] and the resistance of
uiescent CML stem cells to this agent [76]. A phase
I study using 70 mg twice daily is ongoing. Similar
romising activity has been described with AMN107,
nother novel adenosine triphosphate competitive in-
ibitor of BCR-ABL [77]. Although these agents may
epresent useful additional therapies in patients with
matinib-resistant disease and no allogeneic transplant
ption, at present, in the absence of at least medium-
erm safety and efﬁcacy data, these drugs should be
sed only in the context of a clinical trial.
llograft
At this time we recommend an allograft, if avail-
ble, and the anticipated TRM is “acceptable” as the
ntervention of choice in patients with a suboptimal
esponse to imatinib who do not respond to dose
scalation or who have a resistant mutation. In some
ircumstances, such as younger patients with sibling
onors, an allograft is a reasonable ﬁrst-choice alter-
                   
                     
     
   suboptimal response (see text) 
    consider other therapies (Figure 3) 
• 
• 
• 
initiate search for allogeneic
donor in younger patients
Imatinib
monitor with
1.  QPCR BCR-ABL each 3 mths;
     mutation analysis and cytogenetics if significant
     rise in BCR-ABL
2.  routine cytogenetics at 6, 12 months
good molecular or
CG response
ongoing with QPCR each 3-6 months
no transplant if ongoing response; however consider reduced intensity allograft in
patients at low risk of TRM in context of clinical trial
if early evidence of possible resistance (significant rise in BCR-ABL), perform
mutation analysis and cytogenetics.  Treatment dependent on nature of resistance
and other available o
igure 2. Suggested monitoring and treatment algorithm for pa-
ients with newly diagnosed CML-CP1 receiving imatinib. QPCR
ndicates quantitative polymerase chain reaction.ative therapy as soon as suboptimal response is iden- miﬁed. The “salvageability” of imatinib-resistant CML
y allografting is a crucial issue, but there are limited
ublished data thus far. A retrospective review from
he Seattle and City of Hope groups demonstrated a
-year survival of 93% in 28 CP patients previously
reated with imatinib, but only a minority had ima-
inib-resistant disease or clonal evolution [78]. The
rolonged use of imatinib before transplantation did
ot appear to adversely effect TRM.
navailability of New Inhibitors or Allografting
The options in this circumstance include ongoing
matinib, hydroxyurea, interferon, homoharringto-
ine, or experimental therapy within a trial setting.
here is conﬂicting and indirect evidence on the use-
ulness of ongoing imatinib in the context of cytoge-
etic resistance. Two studies have compared the sur-
ival of patients who did not respond to interferon-
nd subsequently obtained no cytogenetic response to
matinib, with historical controls not responding to
nterferon- and subsequently managed with conven-
ional, non-imatinib therapy. The MD Anderson
roup reported a survival beneﬁt for imatinib; a Brit-
sh group found the opposite [79,80].
We are not aware of published clinical studies
valuating the role of interferon- or autografting for
matinib-resistant disease. Interferon- appears to act
gainst CML stem cells, which may harbor mutations
nd be resistant to imatinib whose action is directed
rimarily against committed CML progenitors [81].
n Australian study is currently evaluating the addi-
ion of pegylated interferon to imatinib in patients
ith persistent BCR-ABL positivity. Preliminary re-
ults of the addition of homoharringtonine to imatinib
n patients with persistent BCR-ABL positivity after
matinib alone are promising, with a decrease in tran-
cript level in all 10 patients enrolled [82].
 )SHTNOM( TNIOP-EMIT 
RESPONSE 3 6 12 18 24 
Lack of CHR A B    
Lack of MCR  A B   
Lack of CCR   A B  
Lack of MMR    A  
A: 
B: 
Increase imatinib to 800mg
Consider ceasing imatinib and proceeding to an allograft or, in an allograft not an
option, a second generation kinase inhibitor in the context of a clinical trial.  If
these options not available, consider continuing imatinib as long as 
haematological control is maintained.  See text for discussion.
igure 3. Suggested approach to suboptimal response to imatinib
00 mg/d in the absence of mutational analysis. CHR indicates
omplete hematologic response; MCR, major cytogenetic response
Ph 65%); CCR, complete cytogenetic response; MMR, major
olecular response (3 log reduction in BCR-ABL).
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Figures 2 and 3 summarize a proposed monitoring
nd therapeutic algorithm for patients with newly di-
gnosed CML-CP1, based on the preceding discus-
ion. We recommend an initial trial of imatinib in all
atients and initiating a donor search in those whom
ransplantation is an option if imatinib is ineffective.
n the absence of mutational analysis, an initial trial of
ncreased dose of imatinib is recommended in subop-
imal responders, with an allograft or a second-gener-
tion inhibitor (if available) recommended if there is
o improvement over the subsequent 3 to 6 months.
ote, however, that in patients who do not achieve a
MR at 18 to 24 months, the risk of AP/BC over the
ext 3 to 4 years is only 5% to 10%, so the speciﬁc risk
roﬁle for each patient of intervention with an allo-
raft needs to be very carefully considered in this
ontext. For example, in the context of imatinib resis-
ance, transplantation would be the therapy of choice
n a younger patient with a compatible sibling, but a
rial of a second-generation inhibitor may be pre-
erred in a patient with a high-risk EBMT score.
In reality, each patient with CML will have a
nique mixture of clinical factors such as age, disease
esponse, mutation status, comorbidities, and donor
haracteristics. Accordingly, recommendations as out-
ined in Figures 2 and 3 can be used only as broad
uidelines and therapeutic decisions have to be indi-
idualized. To illustrate this, Table 2 presents the
utcome with various treatment alternatives (imatinib
ose escalation, new tyrosine kinase inhibitors, al-
ografting) in 3 hypothetical clinical scenarios, noting
hat the new inhibitors are only currently available in
linical trials.
CCELERATED PHASE CML
The MD Anderson group recently reported their
xperience with imatinib for CML-AP, describing a
CR of 43% and an estimated 4-year survival of 53%,
he latter results comparable with allografting [87]. In
omparison with 400 mg, imatinib doses of 600 mg
mproved cytogenetic responses, duration of response,
nd overall survival [88]. AP deﬁned by clonal evolu-
ion alone responded particularly well to imatinib,
ith a CCR of 60% and no treatment failures at 1 year
n a cohort of 15 patients [89]. In contrast, results with
matinib are worse in patients with other hematologic
vidence of AP and particularly poor in those with
ematologic criteria and clonal evolution.
Accordingly, imatinib is a reasonable initial option
t presentation in patients with CML-AP deﬁned only
y clonal evolution or in patients with other hemato-
ogic criteria for AP at high risk for early allograft
RM according to the EBMT score, with an allograft
eserved for patients with failure to achieve an early iytogenetic response or in whom progression occurs
fter an initial favorable response.
LAST PHASE CML
Imatinib is not generally effective as a single agent
n CML-BP, with a low incidence of MCR and a
edian survival of 6 to 7 months, although a small
umber of patients has ongoing hematologic re-
ponses up to 2 years after therapy [90,91]. Toxicity is
ess and response rates higher with imatinib compared
ith standard cytarabine combinations [91]. Results
or allografting in CML-BP have generally been poor,
lthough the outcome appears better for patients with
hemosensitive disease transplanted in second CP [92].
For patients who present in CML-BP, have not
reviously received imatinib, and are eligible for a
ransplant, it is reasonable to promptly allograft those
ho achieve a hematologic response, sustained at least
n the short term, to imatinib. An allograft is probably
nappropriate in patients resistant to imatinib or con-
entional chemotherapy and a trial of the newer ty-
osine kinase inhibitors, if available, should be consid-
red.
YNGENEIC TRANSPLANTS
Rarely, patients with CML will have an identical
win. The largest series of syngeneic transplants for
ML described a low TRM (3% at 3 years) but a high
elapse rate, approaching 60% at 52 months after
ransplantation [93]. These transplants have been as-
ociated with GVHD, particularly from parous donors
94], but it is not known whether this translates into a
linically relevant graft-versus-CML effect. A synge-
eic transplant, using myeloablative conditioning and
ith imatinib before and after transplantation, is a
easonable consideration in eligible patients.
UTURE PROSPECTS
Several groups are evaluating treatment with ima-
inib to reduce the CML burden followed by a re-
uced intensity allograft [95] or the reverse, ie, a
educed intensity allograft followed by imatinib [96].
reliminary results suggest a low TRM with these
pproaches but longer-term follow-up is needed to
scertain whether durable remissions can be achieved.
otential studies include (1) myeloablative versus re-
uced intensity conditioning allografts versus newer
yrosine kinase inhibitors for imatinib-resistant dis-
ase and (2) reduced intensity allografts versus ongo-
ng imatinib for imatinib-responsive disease.
Table 2. Three Hypothetical Scenarios
Scenario
Escalated Dose
Imatinib
Second-Generation Tyrosine
Kinase Inhibitors
Allograft
Recommendation
EBMT Risk Score
and 5-y Survival [12] Comment/Limitations
30-y-old male. After 6 mo of imatinib
(400 mg), loss of molecular and CG
response. T315I mutation. AP on
marrow. One antigen mismatched
(at DRB1), female donor (age 25 y).
Unlikely to be effective
as mutant highly
resistant to imatinib
[71]
Inactive in vitro and probably
in vivo against T315I
mutant [73,75]
4; 26% EBMT score does not
distinguish between
matched and mismatched
unrelated donors or
analyze donor age. DRB1
mismatch associated with
worse 5-y survival for
unrelated donor allografts
for CML-CP1 (30  10% vs
45  5% if matched) [83].
Allograft
45-y-old female. After 15 mo of
imatinib (400 mg), loss of molecular
and CG response with G250E
(P loop) mutation, CP on marrow.
Sibling donor (age 55 y).
Unlikely to respond
as most P-loop
mutations, relatively
resistant in vitro to
imatinib [71], but
clinical data limited
Preliminary data suggest
activity against all P-loop
mutants [73,77], but
durability of response not
established
3; 44% Increasing donor age reduces
5-y survival for matched
and mismatched unrelated
allografts [84]
Second-generation tyrosine
kinase inhibitor or
allograft
55-y-old male. 40% Ph after 12 mo of
imatinib (400 mg). No mutation.
Sibling donor.
>20% chance achieving
CCR at 24 mo and
approximately 18%
risk of progression
by 30 mo with no
change in dose
[61,85]. Increase to
800 mg likely to
improve CG
response [63].
Limited data. In phase I
study, BMS-354825
produced cytogenetic
improvement in 40%
patients in late CP
intolerant/resistant to
imatinib [74]. Data
awaited on phase II studies
with BMS-354825 and
AMN107.
3; 44% Minimal data on allograft
outcome in imatinib-
resistant CML, including
optimal intensity of
conditioning regimen in
this context. Fludarabine/
low-dose busulphan
conditioning associated
with improved overall
survival and lower TRM
compared with cyclo-TBI*
in patients >50 y [86]
Increased imatinib dose; if
no response second-
generation tyrosine
kinase inhibitor in the
context of a clinical trial
or reduced intensity
conditioning allograft
*Cyclo-TBI indicates cyclophosphamide plus total body irradiation.
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A. Grigg and T. Hughes804ONCLUSIONS
Based on the most recent data available for alloSCT
nd imatinib, it seems reasonable for clinicians to rec-
mmend to all patients with newly diagnosed CML-
P1 an initial trial of imatinib therapy, reserving
lloSCT for second-line therapy. Selected younger
atients with an estimated low risk of TRM who
xpress a clear preference for a potentially curative
pproach, despite the clinician’s recommendation,
ould still be offered an upfront alloSCT.
Although imatinib has been a major advance in
erms of a greatly decreased risk of early death, the
ast majority of patients will be left with a need for
ife-long therapy and the possibility of resistance and
isease progression some time in the next 5 to 20
ears. Future progress with effective combination
herapy may further improve the outlook for these
atients on long-term imatinib therapy. In the short
erm, the most important issue for patients treated
ith imatinib is regular and accurate disease monitor-
ng so that the minority with suboptimal response or
arly resistance can be identiﬁed at a stage when other
odalities, including allografting, can be effectively
pplied.
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